ArticleNPJ precision oncology2025

ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial.

Thomas J Herzog et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.